🇺🇸 FDA
Pipeline program

AP1189 Tablet, AP1189 Tablet, AP1189 Tablet, Matching Placebo (tablets), Methotrexat-Ebewe, 2,5 mg, tabletki

CS008

Phase 2 small_molecule active

Quick answer

AP1189 Tablet, AP1189 Tablet, AP1189 Tablet, Matching Placebo (tablets), Methotrexat-Ebewe, 2,5 mg, tabletki for Rheumatoid Arthritis is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Lacuna Pharma Pty Ltd
Indication
Rheumatoid Arthritis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials